Abstract--Our objectives was to evaluate erythropoietin (EPO) administration for preoperative autologous blood donation from anemic patients scheduled for orthopedic surgery. EPO was administered to 170 patients intravenously (i.v.) and subcutaneously (s.c.), To compare the difference between i.v. and s.c. administration the hemoglobin recovery rates per 10 000 IU of EPO (uHRR) administered i.v. and s.c. were calculated_ The i.v, and s.c. uHRR increased by 7.0 and 3.3%, respectively, in patients with admission Hb levels below 9.9 g/dt. The acquisition of scheduled blood was feasible for 54.7% and homologous blood transfusion was not needed for 88.7% of severely anemic patients. Eight patients required homologous blood transfusions and seven showed no response to EPO. We conclude that autologous blood transfusion with EPO treatment for anemic patients is safe and useful.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.